CliffBio
biologic

Pombiliti

cipaglucosidase alfa-atga

Loss of exclusivity—loss of exclusivity
CompanyAmicus Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand namePombiliti
Active ingredientcipaglucosidase alfa-atga
Strength105MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Amicus Therapeutics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.